News | Brachytherapy Systems, Women's Healthcare | October 25, 2018

Xoft Electronic Brachytherapy System Effective in Early-Stage Breast Cancer

Multi-center research presented at ASTRO 2018 shows intraoperative radiation therapy with the Xoft System is safe with low recurrence and low morbidity in the treatment of breast cancer

October 25, 2018 — iCAD Inc. announced new clinical research demonstrating positive outcomes supporting the use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the treatment of early-stage breast cancer. Preliminary results demonstrated that intraoperative radiation therapy (IORT) using the Xoft System is safe, with excellent local control and cosmesis, and low morbidity. The analysis of the international, multi-center trial was unveiled during an oral presentation at the 60th American Society for Radiation Oncology (ASTRO) annual meeting, Oct. 21-24 in San Antonio, Texas.

In the presentation, A.M. Nisar Syed, M.D., principle study investigator, and medical director, radiation oncology and endocurietherapy, MemorialCare Cancer Institute, Long Beach Memorial Medical Center, and professor of radiation oncology, UCI Medical Center and Harbor-UCLA School of Medicine, detailed clinical techniques and outcomes of IORT using the Xoft System at the time of breast conserving surgery with findings based upon ASTRO suitability criteria. The trial enrolled 1,201 patients between May 2012 and July 2018 at 28 international and U.S.-based institutions. With a median follow up of two years, less than 1 percent of patients had cancer regrowth (ipsilateral recurrence) or developed new primary cancers in the other breast. Treatment was well tolerated, with grade 3, 4 and 5 adverse events occurring in only 37 patients. Mean treatment time was 10.5 minutes.

“Our research continues to demonstrate significant promise in the treatment of early-stage breast cancer with IORT using the Xoft System. Preliminary outcomes show that a single fraction of radiation with the Xoft System yields excellent results in patients meeting specific selection criteria,” said Syed. “By greatly reducing the number of treatment patients receive as compared to traditional radiation therapy, IORT provides valuable advantages to patients including shorter treatment times, fewer side effects, reduced costs and improved quality of life.”

In addition to the new data release at the annual meeting, iCAD hosted a series of in-booth expert presentations and peer-to-peer learning opportunities led by Syed and other global experts, including:

  • Paulo Costa, M.D., radiation oncologist, Instituto CUF Porto, Breast Surgery Unit Senhora da Hora, Matosinhos, Portugal;
  • Charles Wesley Hodge, M.D., radiation oncologist, Florida Hospital Celebration Health, Celebration, Fla.; and
  • Chun-Shu Lin, M.D., chief, Department of Radiation Oncology, Tri-Service General Hospital, Taipei City, Taiwan.

IORT with the Xoft System uses a miniaturized X-ray source to deliver one precise, concentrated dose of radiation to a tumor site at the time of breast-conserving surgery (lumpectomy). The treatment can be completed in as little as eight minutes, making it possible for appropriately selected patients to replace six to eight weeks of post-operative external beam radiation therapy (EBRT) with a single treatment.

The Xoft System is cleared by the U.S. Food and Drug Administration, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancer, and gynecological cancers.

For more information: www.xoftinc.com

Related Content

Rebrand reflects Volpara Health's mission to prevent advanced-stage breast cancer
News | Breast Imaging | October 19, 2020
October 19, 2020 — Volpara Solutions, a leader in AI-powered breast density assessment, announced that it has changed
Moffitt Cancer Center researchers are developing a noninvasive, accurate method to analyze a patient's tumor mutations and biomarkers to determine the best course of treatment.

Getty Images

News | Lung Imaging | October 19, 2020
October 19, 2020 — Personalized treatment options for patients with...
Varian, a leading provider of cancer care technologies and solutions, continues to reinforce its commitment to delivering Intelligent Cancer Care during the 2020 American Society for Radiation Oncology (ASTRO) taking place virtually Oct. 24-31.
News | ASTRO | October 19, 2020
October 19, 2020 — ...
Mevion Medical Systems announced that it has shipped the accelerator module for the Mevion S250i Proton Therapy System to Kunshan, China. The 15-ton compact accelerator, the heart of the proton therapy system, is the smallest of its kind and will be the first in China.

Mevion's compact accelerator module is lifted and placed on a truck for the first leg of its journey to China. (Photo: Business Wire)

News | Proton Therapy | October 16, 2020
October 16, 2020 — Mevion Medical Systems announced that it has shipped the accelerator module for the...
More than 600,000 women die of advanced breast cancer annually. (1) There is a safe, universally obtainable method to reduce this terrible toll according to MammaCare Foundation scientist Mark Kane Goldstein, Ph.D.

Module 1

News | Women's Health | October 15, 2020
October 15, 2020 — More than 600,000 women die of advanced breast cancer annually. ...
Conducted by the University of Gothenburg, Lund University and the University of South Australia, the preclinical study found that dietary oat bran can offset chronic gastrointestinal damage caused by radiotherapy, contradicting long-held clinical recommendations.

Getty Images

News | Radiation Therapy | October 07, 2020
October 7, 2020 — Loved or hated, the humble oat could be the new superfood for cancer patients as international ...